PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 Просмотры
• 07/08/23
0
0
встраивать
administrator
Подписчики
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
Показать больше
Комментарии Facebook
SORT BY-
Лучшие комментарии
-
Последние комментарии